E
ABVC BioPharma, Inc.
ABVC
$1.08
$0.000.00%
E
Sell
3/24/2023Downgrade
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 03/24/2023.
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 03/24/2023.
D
Sell
3/9/2023Upgraded
ABVC BioPharma, Inc. (ABVC) was upgraded to D- from E+ on 3/9/2023 due to an increase in the volatility index, total return index and valuation index.
ABVC BioPharma, Inc. (ABVC) was upgraded to D- from E+ on 3/9/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
11/21/2022Downgrade
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 11/21/2022 due to a noticeable decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.06 to -$0.1137, total revenue declined 86.48% from $312.9 to $42.3, and EBIT declined 81.53% from -$2.05M to -$3.72M.
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 11/21/2022 due to a noticeable decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.06 to -$0.1137, total revenue declined 86.48% from $312.9 to $42.3, and EBIT declined 81.53% from -$2.05M to -$3.72M.
D
Sell
5/18/2022Upgraded
ABVC BioPharma, Inc. (ABVC) was upgraded to D- from E+ on 5/18/2022 due to a noticeable increase in the growth index, volatility index and valuation index. Total revenue increased 167.99% from -$37.8 to $25.7, earnings per share increased from -$0.3166 to -$0.202, and EBIT increased 3.54% from -$6.45M to -$6.22M.
ABVC BioPharma, Inc. (ABVC) was upgraded to D- from E+ on 5/18/2022 due to a noticeable increase in the growth index, volatility index and valuation index. Total revenue increased 167.99% from -$37.8 to $25.7, earnings per share increased from -$0.3166 to -$0.202, and EBIT increased 3.54% from -$6.45M to -$6.22M.
E
Sell
4/18/2022Downgrade
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 4/18/2022 due to a noticeable decline in the growth index. Earnings per share declined from -$0.07 to -$0.3166, EBIT declined 227.17% from -$1.97M to -$6.45M, and total revenue declined 138.18% from $99 to -$37.8.
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 4/18/2022 due to a noticeable decline in the growth index. Earnings per share declined from -$0.07 to -$0.3166, EBIT declined 227.17% from -$1.97M to -$6.45M, and total revenue declined 138.18% from $99 to -$37.8.
D
Sell
11/17/2021Upgraded
ABVC BioPharma, Inc. (ABVC) was upgraded to D- from E+ on 11/17/2021 due to a major increase in the solvency index, growth index and valuation index. The quick ratio increased from 0.34 to 1.41, total revenue increased 215.29% from $31.4 to $99, and debt to equity declined from 3.61 to 0.24.
ABVC BioPharma, Inc. (ABVC) was upgraded to D- from E+ on 11/17/2021 due to a major increase in the solvency index, growth index and valuation index. The quick ratio increased from 0.34 to 1.41, total revenue increased 215.29% from $31.4 to $99, and debt to equity declined from 3.61 to 0.24.
E
Sell
10/1/2021Downgrade
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 10/1/2021 due to a major decline in the total return index.
ABVC BioPharma, Inc. (ABVC) was downgraded to E+ from D- on 10/1/2021 due to a major decline in the total return index.
D
Sell
8/13/2021Downgrade
ABVC BioPharma, Inc. (ABVC) was downgraded to D- from D on 8/13/2021 due to a noticeable decline in the growth index, solvency index and valuation index. Total revenue declined 88.07% from $263.2 to $31.4, debt to equity increased from 2.01 to 3.61, and EBIT declined 62.49% from -$1.25M to -$2.04M.
ABVC BioPharma, Inc. (ABVC) was downgraded to D- from D on 8/13/2021 due to a noticeable decline in the growth index, solvency index and valuation index. Total revenue declined 88.07% from $263.2 to $31.4, debt to equity increased from 2.01 to 3.61, and EBIT declined 62.49% from -$1.25M to -$2.04M.
D
Sell
5/12/2021Upgraded
ABVC BioPharma, Inc. (ABVC) was upgraded to D from D- on 5/12/2021 due to a large increase in the growth index, total return index and solvency index. Total revenue increased 323.15% from $62.2 to $263.2, earnings per share increased from -$0.2444 to -$0.05, and EBIT increased 74.17% from -$4.85M to -$1.25M.
ABVC BioPharma, Inc. (ABVC) was upgraded to D from D- on 5/12/2021 due to a large increase in the growth index, total return index and solvency index. Total revenue increased 323.15% from $62.2 to $263.2, earnings per share increased from -$0.2444 to -$0.05, and EBIT increased 74.17% from -$4.85M to -$1.25M.
D
Sell
3/17/2021Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to D- from D on 3/17/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 862.53% from -$328.8 to -$3.16M, EBIT declined 276.07% from -$1.29M to -$4.85M, and earnings per share declined from -$0.0947 to -$0.2444.
American BriVision (Holding) Corporation (ABVC) was downgraded to D- from D on 3/17/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 862.53% from -$328.8 to -$3.16M, EBIT declined 276.07% from -$1.29M to -$4.85M, and earnings per share declined from -$0.0947 to -$0.2444.
D
Sell
12/10/2020Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to D from D- on 12/10/2020 due to an increase in the volatility index, total return index and solvency index. The quick ratio increased from 0.12 to 0.18, and debt to equity declined from -4.33 to -5.34.
American BriVision (Holding) Corporation (ABVC) was upgraded to D from D- on 12/10/2020 due to an increase in the volatility index, total return index and solvency index. The quick ratio increased from 0.12 to 0.18, and debt to equity declined from -4.33 to -5.34.
D
Sell
5/15/2020Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to D- from E+ on 5/15/2020 due to a large increase in the growth index and valuation index. Earnings per share increased from -$0.0639 to -$0.0617.
American BriVision (Holding) Corporation (ABVC) was upgraded to D- from E+ on 5/15/2020 due to a large increase in the growth index and valuation index. Earnings per share increased from -$0.0639 to -$0.0617.
E
Sell
5/6/2020Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to E+ from E on 5/6/2020 due to an increase in the growth index and total return index.
American BriVision (Holding) Corporation (ABVC) was upgraded to E+ from E on 5/6/2020 due to an increase in the growth index and total return index.
E
Sell
4/21/2020Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to E from E+ on 4/21/2020 due to a decline in the volatility index and valuation index.
American BriVision (Holding) Corporation (ABVC) was downgraded to E from E+ on 4/21/2020 due to a decline in the volatility index and valuation index.
E
Sell
4/6/2020Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to E+ from E on 4/6/2020 due to an increase in the volatility index and valuation index.
American BriVision (Holding) Corporation (ABVC) was upgraded to E+ from E on 4/6/2020 due to an increase in the volatility index and valuation index.
E
Sell
3/18/2020Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to E from E+ on 3/18/2020 due to a decline in the volatility index, total return index and valuation index.
American BriVision (Holding) Corporation (ABVC) was downgraded to E from E+ on 3/18/2020 due to a decline in the volatility index, total return index and valuation index.
E
Sell
2/28/2020Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to E+ from E on 2/28/2020 due to an increase in the volatility index and valuation index.
American BriVision (Holding) Corporation (ABVC) was upgraded to E+ from E on 2/28/2020 due to an increase in the volatility index and valuation index.
E
Sell
2/12/2020Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to E from E+ on 2/12/2020 due to a decline in the volatility index, solvency index and total return index.
American BriVision (Holding) Corporation (ABVC) was downgraded to E from E+ on 2/12/2020 due to a decline in the volatility index, solvency index and total return index.
E
Sell
11/19/2019Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to E+ from D- on 11/19/2019 due to a large decline in the efficiency index, volatility index and total return index. Net income declined 117.88% from -$557.6 to -$1.21M.
American BriVision (Holding) Corporation (ABVC) was downgraded to E+ from D- on 11/19/2019 due to a large decline in the efficiency index, volatility index and total return index. Net income declined 117.88% from -$557.6 to -$1.21M.
D
Sell
5/29/2019Downgrade
American BriVision (Holding) Corporation (ABVCD) was downgraded to D- from D on 5/29/2019 due to a significant decline in the efficiency index, volatility index and total return index.
American BriVision (Holding) Corporation (ABVCD) was downgraded to D- from D on 5/29/2019 due to a significant decline in the efficiency index, volatility index and total return index.
D
Sell
4/16/2019Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to D from D+ on 4/16/2019 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.001 to -$0.0163, EBIT declined 306.94% from -$175.7 to -$715, and operating cash flow declined 85.47% from -$53 to -$98.3.
American BriVision (Holding) Corporation (ABVC) was downgraded to D from D+ on 4/16/2019 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.001 to -$0.0163, EBIT declined 306.94% from -$175.7 to -$715, and operating cash flow declined 85.47% from -$53 to -$98.3.
D
Sell
10/30/2018Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to D+ from C- on 10/30/2018 due to a noticeable decline in the volatility index and total return index.
American BriVision (Holding) Corporation (ABVC) was downgraded to D+ from C- on 10/30/2018 due to a noticeable decline in the volatility index and total return index.
C
Hold
8/21/2018Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to C- from D on 8/21/2018 due to a significant increase in the efficiency index and solvency index. The quick ratio increased from 0.57 to 0.61.
American BriVision (Holding) Corporation (ABVC) was upgraded to C- from D on 8/21/2018 due to a significant increase in the efficiency index and solvency index. The quick ratio increased from 0.57 to 0.61.
D
Sell
5/25/2018Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to D from D+ on 5/25/2018 due to a significant decline in the efficiency index, total return index and growth index. Total capital declined 198.86% from -$646.9 to -$1.93M, and operating cash flow declined 23.5% from -$111.5 to -$137.7.
American BriVision (Holding) Corporation (ABVC) was downgraded to D from D+ on 5/25/2018 due to a significant decline in the efficiency index, total return index and growth index. Total capital declined 198.86% from -$646.9 to -$1.93M, and operating cash flow declined 23.5% from -$111.5 to -$137.7.
D
Sell
2/1/2018Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to D+ from D on 2/1/2018 due to a significant increase in the efficiency index.
American BriVision (Holding) Corporation (ABVC) was upgraded to D+ from D on 2/1/2018 due to a significant increase in the efficiency index.
D
Sell
1/17/2018Downgrade
American BriVision (Holding) Corporation (ABVC) was downgraded to D from D+ on 1/17/2018 due to a significant decline in the efficiency index, growth index and total return index. EBIT declined 3,437.29% from -$99.5 to -$3.52M, earnings per share declined from -$0.0006 to -$0.0174, and net income declined 2,673.34% from -$127.9 to -$3.55M.
American BriVision (Holding) Corporation (ABVC) was downgraded to D from D+ on 1/17/2018 due to a significant decline in the efficiency index, growth index and total return index. EBIT declined 3,437.29% from -$99.5 to -$3.52M, earnings per share declined from -$0.0006 to -$0.0174, and net income declined 2,673.34% from -$127.9 to -$3.55M.
D
Sell
10/20/2017Upgraded
American BriVision (Holding) Corporation (ABVC) was upgraded to D+ from D on 10/20/2017 due to a significant increase in the efficiency index, total return index and growth index. Operating cash flow increased 88.59% from -$862.2 to -$98.4, EBIT increased 57.98% from -$236.8 to -$99.5, and net income increased 50.18% from -$256.7 to -$127.9.
American BriVision (Holding) Corporation (ABVC) was upgraded to D+ from D on 10/20/2017 due to a significant increase in the efficiency index, total return index and growth index. Operating cash flow increased 88.59% from -$862.2 to -$98.4, EBIT increased 57.98% from -$236.8 to -$99.5, and net income increased 50.18% from -$256.7 to -$127.9.
D
Sell
7/16/2015Downgrade
Ecology Coatings, Inc. (ECOCQ) was downgraded to D from D+ on 7/16/2015 due to a significant decline in the valuation index.
Ecology Coatings, Inc. (ECOCQ) was downgraded to D from D+ on 7/16/2015 due to a significant decline in the valuation index.
D
Sell
5/28/2015Downgrade
Ecology Coatings, Inc. (ECOCQ) was downgraded to D+ from C- on 5/28/2015 due to a major decline in the growth index, efficiency index and solvency index. EBIT declined 20% from -$1 to -$800, net income declined 20% from -$1 to -$800, and debt to equity increased from 0.54 to 0.56.
Ecology Coatings, Inc. (ECOCQ) was downgraded to D+ from C- on 5/28/2015 due to a major decline in the growth index, efficiency index and solvency index. EBIT declined 20% from -$1 to -$800, net income declined 20% from -$1 to -$800, and debt to equity increased from 0.54 to 0.56.
C
Hold
4/20/2015Upgraded
Ecology Coatings, Inc. (ECOCQ) was upgraded to C- from on 4/20/2015 due to a significant increase in the solvency index, valuation index and volatility index.
Ecology Coatings, Inc. (ECOCQ) was upgraded to C- from on 4/20/2015 due to a significant increase in the solvency index, valuation index and volatility index.
NASDAQ
05/06/2024 4:00PM Eastern
Quotes delayed
